Clinical trials: Progression-free Survival
Glioblastoma
Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma
Despite an aggressive therapeutic approach, the prognosis for most patients with glioblastoma (GBM) remains poor. The relationship between non-invasive Magnetic Resonance Imaging (MRI) biomarkers at preoperative, postradiotherapy…
- Trial name
- ONCOhabitats (NCT03439332)
- Where
- Spain
- Volunteers
- 305 people
- Sponsor
- Juan M Garcia-Gomez
Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer patients.
- Conditions
- Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced, Epithelial Ovarian Cancer, Colony Stimulating Factors Adverse Reaction
- Trial name
- NCT04101760
- Testing
- Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lei Li
Progression-free Survival Was Defined From Date of Surgery to Disease Progression Post-surgery or Death or Last Follow-up, Overall Survival Was Defined as Time From Surgery to Death From Any Cause or Last Follow-up
Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer
This is a large non-interventional observational bidirectional study planned to collect clinically relevant data and prognostic follow-up information of patients with cervical cancer who were seen at our center from 2010.01.01 to…
- Trial name
- NCT06480617
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed.
- Trial name
- NCT03976843
- Testing
- 18F-DCFPyL
- Where
- 6 sites in United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Lymphocytic Leukemia, Chronic
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT01998880
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Advanced Malignant Solid Tumors
Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors
In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors.
- Trial name
- NCT05749627
- Testing
- Neoantigen peptide vaccine, Neoantigen-based DC immune preparation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Glioblastoma Multiforme
Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]
Glioblastoma multiforme (GBM WHO IV) is the most common and aggressive primary brain tumor in adults, carrying a poor prognosis with a median survival of 12-16 months.
- Trial name
- TYR-GLIO (NCT06466031)
- Testing
- MRI & PET fusion, MRI+T1C
- Where
- Poland
- Volunteers
- 189 people
- Sponsor
- Copernicus Memorial Hospital
Liver Cancer
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00605722
- Testing
- bevacizumab (Avastin), erlotinib (Tarceva)
- Where
- 6 sites in Philippines, South Korea and 1 more
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Graft-Versus-Host Disease, Hematological Malignancies
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
The present project is a multicenter phase II trail aiming at comparing which of the two postgrafting immunosuppressive regimens proposed in this study will be best suited to prevent graft-versus-host disease (GVDH).
- Trial name
- NCT01428973
- Testing
- Mycophenolate mofetil, Sirolimus
- Where
- 13 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- University of Liege
Rectal Neoplasms
Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma
Many data suggest that patients with low rectal adenocarcinoma who achieved ypT0N0 status have improved survival and disease-free survival (DFS) compared to all other stages however only few data are available regarding the…
- Trial name
- NCT03601689
- Testing
- rectal resection
- Where
- 8 sites in Algeria, Morocco
- Volunteers
- 84 people
- Sponsor
- Moroccan Society of Surgery
Colorectal Cancer
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and…
- Trial name
- NCT01116271
- Testing
- AZD6244, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Lung Cancer
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897533
- Testing
- gene mapping, polymorphism analysis, diagnostic laboratory biomarker analysis
- Volunteers
- 137 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Seminoma, Stage II
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study. Patients with stage IIa/IIb < 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of…
- Trial name
- EDEN (NCT05529251)
- Testing
- Radiotherapy boost, Carboplatin AUC7, 3 cycles of EP
- Where
- 15 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Leon Berard
Metastatic Breast Cancer
Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer
The goal of the study is to understand the meaning of progression-free survival for women with metastatic breast cancer and to use this understanding to create and distribute a new questionnaire to assess the effect progression…
- Trial name
- NCT01282931
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Health Outcomes Solutions
Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian…
- Conditions
- Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07591831
- Testing
- Liposomal Irinotecan
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Glioblastoma, Sarcoma
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression.
- Conditions
- Glioblastoma, Sarcoma, Neuroblastoma
- Trial name
- NCT01174537
- Testing
- New Castle Disease Virus
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Advanced Cancer, Olanzapine
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal…
- Conditions
- Advanced Cancer, Olanzapine, Progression Free Survival
- Trial name
- NCT06338683
- Testing
- Olanzapine 2.5 MG, Standard anti-tumor treatment, Nutritional advice
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Qinghai Red Cross Hospital
Squamous Cell Carcinoma of the Penis
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)
The purpose of this study is to evaluate the efficacy and safety of Cetuximab in metastatic penile carcinoma
- Trial name
- PENILANE (NCT02014831)
- Testing
- Cetuximab, TIP
- Where
- 7 sites in France
- Sponsor
- Centre Leon Berard
Metastatic Gastric Cancer
Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Elderly patients are generally underrepresented in the study populations of combination chemotherapy trials. In gastric cancer patients, oxaliplatin has shown a more favorable toxicity profile than cisplatin.
- Trial name
- MATURE (NCT02002195)
- Testing
- FOLFOX, Capecitabine
- Where
- 2 sites in Italy
- Volunteers
- 47 people
- Sponsor
- International Group of Endovascular Oncology
Breast Cancer, Neoplasm Metastasis
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red…
- Trial name
- NCT00338286
- Testing
- Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
- Where
- 174 sites in United States, Argentina and 19 more
- Volunteers
- 2,098 people
- Sponsor
- Janssen Research & Development, LLC